| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WILMINGTON, N.C.—In early December, PPD Inc. expanded its early development research services by adding significant neuroscience and ethno-bridging expertise, broadening its capabilities to provide increased access to patients and special populations at PPD-owned clinical research units (CRUs).
 
To enhance its ability to conduct complex, procedurally intensive Phase 1 and Phase 1b early development clinical research in neurology, PPD has added a 52-bed CRU in Orlando, Fla. The recently acquired unit reportedly has a strong track record of recruiting and conducting early phase trials in multiple neurological indications, such as Alzheimer’s disease. The Orlando CRU has completed more than 50 Phase 1 studies in Alzheimer's and other central nervous system/neurodegenerative therapeutic areas.
 
Additionally, PPD’s Las Vegas CRU—a hospital-adjacent, 24-bed unit specializing in endocrinology and metabolic trials—has expanded its portfolio to include the conduct of Japanese ethno-bridging studies. These studies allow biopharmaceutical companies to incorporate Asian patient data in parallel with western regions to initiate Phase 3 studies in Asian markets sooner.
 
“By tapping into nearby high-concentration Japanese communities, we are able to study the way this population metabolizes medications and recommend alterations in safety, efficacy or dosages,” said Scott Dove, vice president of early development at PPD. “In addition to ethno-bridging, we have expanded our distinct capabilities in neuroscience and other niche therapeutic areas to study patient populations more reflective of the products’ end-users. Increasing client access to special patient populations opens exciting opportunities for the development of important new therapies to address unmet medical needs.”

Related Topics

Published In

Volume 15 - Issue 12 | December 2019

December 2019

December 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue